Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum

Saved in:
Bibliographic Details
Main Authors: Nika Kotnik, MD, Gilles F.H. Diercks, MD, PhD, Hilde Jalving, MD, PhD, Geke A.P. Hospers, MD, PhD, Sjoukje F. Oosting, MD, PhD, Michel van Kruchten, MD, PhD, T. Jeroen N. Hiltermann, MD, PhD, Maria C. Bolling, MD, PhD, Jeroen Bremer, PhD, Barbara Horváth, MD, PhD, Joost M. Meijer, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:JAAD Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512625001456
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849470210298347520
author Nika Kotnik, MD
Gilles F.H. Diercks, MD, PhD
Hilde Jalving, MD, PhD
Geke A.P. Hospers, MD, PhD
Sjoukje F. Oosting, MD, PhD
Michel van Kruchten, MD, PhD
T. Jeroen N. Hiltermann, MD, PhD
Maria C. Bolling, MD, PhD
Jeroen Bremer, PhD
Barbara Horváth, MD, PhD
Joost M. Meijer, MD, PhD
author_facet Nika Kotnik, MD
Gilles F.H. Diercks, MD, PhD
Hilde Jalving, MD, PhD
Geke A.P. Hospers, MD, PhD
Sjoukje F. Oosting, MD, PhD
Michel van Kruchten, MD, PhD
T. Jeroen N. Hiltermann, MD, PhD
Maria C. Bolling, MD, PhD
Jeroen Bremer, PhD
Barbara Horváth, MD, PhD
Joost M. Meijer, MD, PhD
author_sort Nika Kotnik, MD
collection DOAJ
format Article
id doaj-art-1505d6ec01294cc69fed56a17b565d8a
institution Kabale University
issn 2352-5126
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series JAAD Case Reports
spelling doaj-art-1505d6ec01294cc69fed56a17b565d8a2025-08-20T03:25:12ZengElsevierJAAD Case Reports2352-51262025-07-016110010610.1016/j.jdcr.2025.03.021Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrumNika Kotnik, MD0Gilles F.H. Diercks, MD, PhD1Hilde Jalving, MD, PhD2Geke A.P. Hospers, MD, PhD3Sjoukje F. Oosting, MD, PhD4Michel van Kruchten, MD, PhD5T. Jeroen N. Hiltermann, MD, PhD6Maria C. Bolling, MD, PhD7Jeroen Bremer, PhD8Barbara Horváth, MD, PhD9Joost M. Meijer, MD, PhD10Department of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the Netherlands; Division of Experimental Allergy and Immunodermatology, University of Oldenburg, Oldenburg, GermanyDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the Netherlands; Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the NetherlandsDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the NetherlandsDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the NetherlandsDepartment of Dermatology, University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), Groningen, the Netherlands; Correspondence to: Joost M. Meijer, MD, PhD, Department of Dermatology, University Medical Center Groningen, Hanzeplein 1, Groningen, 9700 RB, the Netherlands.http://www.sciencedirect.com/science/article/pii/S2352512625001456autoimmune bullous diseasebullous pemphigoidcheckpoint inhibitorimmune-related adverse effectimmunotherapy
spellingShingle Nika Kotnik, MD
Gilles F.H. Diercks, MD, PhD
Hilde Jalving, MD, PhD
Geke A.P. Hospers, MD, PhD
Sjoukje F. Oosting, MD, PhD
Michel van Kruchten, MD, PhD
T. Jeroen N. Hiltermann, MD, PhD
Maria C. Bolling, MD, PhD
Jeroen Bremer, PhD
Barbara Horváth, MD, PhD
Joost M. Meijer, MD, PhD
Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
JAAD Case Reports
autoimmune bullous disease
bullous pemphigoid
checkpoint inhibitor
immune-related adverse effect
immunotherapy
title Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
title_full Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
title_fullStr Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
title_full_unstemmed Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
title_short Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
title_sort pemphigoid diseases as immune related adverse effect following immune checkpoint inhibitors a clinical case series of a diverse spectrum
topic autoimmune bullous disease
bullous pemphigoid
checkpoint inhibitor
immune-related adverse effect
immunotherapy
url http://www.sciencedirect.com/science/article/pii/S2352512625001456
work_keys_str_mv AT nikakotnikmd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT gillesfhdiercksmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT hildejalvingmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT gekeaphospersmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT sjoukjefoostingmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT michelvankruchtenmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT tjeroennhiltermannmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT mariacbollingmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT jeroenbremerphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT barbarahorvathmdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum
AT joostmmeijermdphd pemphigoiddiseasesasimmunerelatedadverseeffectfollowingimmunecheckpointinhibitorsaclinicalcaseseriesofadiversespectrum